The “extreme phenotype approach” applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles

In oncogenetics, some patients could be considered as “extreme phenotypes”, such as those with very early onset presentation or multiple primary malignancies, unusually high numbers of cancers of the same spectrum or rare cancer types in the same parental branch. For these cases, a genetic predisposition is very likely, but classical candidate gene panel analyses often and frustratingly remains negative. In the framework of the EX2TRICAN project, exploring unresolved extreme cancer phenotypes, we applied exome sequencing on rare familial cases with male breast cancer, identifying a novel pathogenic variant of ATR (p.Leu1808*). ATR has already been suspected as being a predisposing gene to breast cancer in women. We next identified 3 additional ATR variants in a cohort of both male and female with early onset and familial breast cancers (c.7762-2A>C; c.2078+1G>A; c.1A>G). Further molecular and cellular investigations showed impacts on transcripts for variants affecting splicing sites and reduction of ATR expression and phosphorylation of the ATR substrate CHEK1. This work further demonstrates the interest of an extended genetic analysis such as exome sequencing to identify very rare variants that can play a role in cancer predisposition in extreme phenotype cancer cases unexplained by classical cancer gene panels testing.

[1]  A. Spurdle,et al.  SPiP: Splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing , 2022, Human mutation.

[2]  Marc S. Williams,et al.  Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network , 2021, JNCI cancer spectrum.

[3]  S. Steinberg,et al.  Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. , 2021, Cancer cell.

[4]  A. Melcher,et al.  ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment , 2019, Clinical Cancer Research.

[5]  B. Bonanni,et al.  Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy , 2019, International journal of cancer.

[6]  M. Bihoreau,et al.  Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing , 2018, International journal of cancer.

[7]  Sitao Wu,et al.  Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA Oncology.

[8]  M. Hung,et al.  Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. , 2018, American journal of cancer research.

[9]  M. Tainsky,et al.  Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability , 2017, PloS one.

[10]  A. Lerário,et al.  A new POT1 germline mutation—expanding the spectrum of POT1-associated cancers , 2017, Familial Cancer.

[11]  N. Rhind,et al.  The Intra-S Checkpoint Responses to DNA Damage , 2017, Genes.

[12]  F. Couch,et al.  Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results , 2016, Breast Cancer Research and Treatment.

[13]  Alexander Hoischen,et al.  New insights into the generation and role of de novo mutations in health and disease , 2016, Genome Biology.

[14]  R. Scott,et al.  Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Broderick,et al.  Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer , 2016, Nature Communications.

[16]  N. Seyfried,et al.  ATRIP Deacetylation by SIRT2 Drives ATR Checkpoint Activation by Promoting Binding to RPA-ssDNA. , 2016, Cell reports.

[17]  S. Fox,et al.  The cancer genetics and pathology of male breast cancer , 2016, Histopathology.

[18]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[19]  J. Benítez,et al.  BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study , 2015, Familial Cancer.

[20]  Abdelghani Mazouzi,et al.  DNA replication stress: causes, resolution and disease. , 2014, Experimental cell research.

[21]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[22]  Cailyn H. Spurrell Identifying New Genes for Inherited Breast Cancer by Exome Sequencing , 2014 .

[23]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[24]  M. King,et al.  Germline Mutations of Inhibins in Early-Onset Ovarian Epithelial Tumors , 2013, Human mutation.

[25]  P. Ang,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[26]  K. Boycott,et al.  Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.

[27]  D. Goldstein,et al.  Genic Intolerance to Functional Variation and the Interpretation of Personal Genomes , 2013, PLoS genetics.

[28]  J. Ferlay,et al.  An international comparison of male and female breast cancer incidence rates , 2013, International journal of cancer.

[29]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[30]  D. Eccles,et al.  Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas , 2013, Nature Genetics.

[31]  A. Fischer,et al.  Primary Microcephaly, Impaired DNA Replication, and Genomic Instability Caused by Compound Heterozygous ATR Mutations , 2013, Human mutation.

[32]  P. Jeggo,et al.  Identification of the First ATRIP–Deficient Patient and Novel Mutations in ATR Define a Clinical Spectrum for ATR–ATRIP Seckel Syndrome , 2012, PLoS genetics.

[33]  R. Tothill,et al.  Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles , 2012, PLoS genetics.

[34]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[35]  G. McArthur,et al.  Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells , 2012, Oncogene.

[36]  Aung Ko Win,et al.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Yuhki Yanase,et al.  Germline mutation in ATR in autosomal- dominant oropharyngeal cancer syndrome. , 2012, American journal of human genetics.

[38]  O. Fernandez-Capetillo,et al.  Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. , 2012, The Journal of clinical investigation.

[39]  M. Barbacid,et al.  Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.

[40]  A. Knudson,et al.  A continuum model for tumour suppression , 2011, Nature.

[41]  P. Oefner,et al.  Rare variants in the ATM gene and risk of breast cancer , 2011, Breast Cancer Research.

[42]  J. Benítez,et al.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.

[43]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[44]  B. Nabet,et al.  Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. , 2010, Cancer research.

[45]  S. Kaufmann,et al.  Prospects for the Use of ATR Inhibitors to Treat Cancer , 2010, Pharmaceuticals.

[46]  J. Bergh,et al.  Multidisciplinary meeting on male breast cancer: summary and research recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[48]  J. Potter,et al.  Lynch Syndrome–Associated Breast Cancers: Clinicopathologic Characteristics of a Case Series from the Colon Cancer Family Registry , 2010, Clinical Cancer Research.

[49]  T. Halazonetis,et al.  Emerging common themes in regulation of PIKKs and PI3Ks , 2009, The EMBO journal.

[50]  F. Mulero,et al.  A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging , 2009, Nature Genetics.

[51]  K. Ko,et al.  Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response , 2009, Nucleic acids research.

[52]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[53]  J. Kobayashi,et al.  Inactivation of the Nijmegen breakage syndrome gene leads to excess centrosome duplication via the ATR/BRCA1 pathway. , 2009, Cancer research.

[54]  S. Shanley,et al.  The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome , 2009, British Journal of Cancer.

[55]  J. Foekens,et al.  CHEK2 1100delC and male breast cancer in the Netherlands , 2009, Breast Cancer Research and Treatment.

[56]  S. Elledge,et al.  How ATR turns on: TopBP1 goes on ATRIP with ATR. , 2008, Genes & development.

[57]  A. van den Berg,et al.  ATR alterations in Hodgkin's lymphoma. , 2008, Oncology reports.

[58]  O. Fernandez-Capetillo,et al.  ATR signaling can drive cells into senescence in the absence of DNA breaks. , 2008, Genes & development.

[59]  Giovanni Parmigiani,et al.  Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[60]  S. Thibodeau,et al.  Mutations in the ataxia telangiectasia and rad3‐related–checkpoint kinase 1 DNA damage response axis in colon cancers , 2007, Genes, chromosomes & cancer.

[61]  P. Jeggo,et al.  Cellular and clinical impact of haploinsufficiency for genes involved in ATR signaling. , 2007, American journal of human genetics.

[62]  D. Labuda,et al.  Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families , 2006, BMC Cancer.

[63]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[64]  Penny A. Jeggo,et al.  The role of double-strand break repair — insights from human genetics , 2006, Nature Reviews Genetics.

[65]  S. Boulton,et al.  Distinct modes of ATR activation after replication stress and DNA double‐strand breaks in Caenorhabditis elegans , 2005, The EMBO journal.

[66]  J. Chien,et al.  Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. , 2005, Cancer research.

[67]  S. Batzoglou,et al.  Distribution and intensity of constraint in mammalian genomic sequence. , 2005, Genome research.

[68]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[69]  L. Maquat,et al.  Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. , 2005, Current opinion in cell biology.

[70]  Robert Winqvist,et al.  Mutation analysis of the ATR gene in breast and ovarian cancer families , 2005, Breast Cancer Research.

[71]  M. Pacek,et al.  Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. , 2005, Genes & development.

[72]  K. Aozasa,et al.  Alterations of DNA damage-response genes ATM and ATR in pyothorax-associated lymphoma , 2005, Laboratory Investigation.

[73]  W. Cliby,et al.  Ataxia Telangiectasia Mutated (ATM) and ATM and Rad3-related Protein Exhibit Selective Target Specificities in Response to Different Forms of DNA Damage* , 2005, Journal of Biological Chemistry.

[74]  Helen Swede,et al.  Epidemiology of male breast cancer. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[75]  J. Boyd,et al.  Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome , 2004, Breast Cancer Research and Treatment.

[76]  Judith A. Goodship,et al.  A splicing mutation affecting expression of ataxia–telangiectasia and Rad3–related protein (ATR) results in Seckel syndrome , 2003, Nature Genetics.

[77]  D. Baltimore,et al.  Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. , 2003, Genes & development.

[78]  R. Mariani-Costantini,et al.  BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. , 2003, Cancer research.

[79]  T. Glover,et al.  ATR Regulates Fragile Site Stability , 2002, Cell.

[80]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[81]  The Polish Breast Cancer Consortium Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[82]  Jun Qin,et al.  ATR and ATRIP: Partners in Checkpoint Signaling , 2001, Science.

[83]  S. Schreiber,et al.  ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[84]  O. Olopade,et al.  Male breast cancer in Cowden syndrome patients with germlinePTEN mutations , 2001, Journal of medical genetics.

[85]  O. Olopade,et al.  Male breast cancer in Cowden syndrome patients with germline PTEN mutations , 2001 .

[86]  A. Carr,et al.  Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice , 2000, Current Biology.

[87]  D. Baltimore,et al.  ATR disruption leads to chromosomal fragmentation and early embryonic lethality. , 2000, Genes & development.

[88]  B. Ponder,et al.  High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. , 1999, Cancer research.

[89]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[90]  B. Ponder,et al.  Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. , 1997, American journal of human genetics.